Lung Cancer Treatment

Understand lung cancer treatment — surgery, chemotherapy, targeted therapy, immunotherapy, and radiation. Navigate your treatment options with Gaf Healthcare's expert oncology network.

Estimated cost: $4,000 – $9,000 · Average stay: 7–10 days

Lung cancer is the leading cause of cancer-related mortality worldwide, responsible for approximately 1.8 million deaths annually. It is broadly classified into two histological categories — Non-Small Cell Lung Cancer (NSCLC, 85% of cases) and Small Cell Lung Cancer (SCLC, 15%) — with fundamentally different biological behaviour, staging systems, and treatment approaches.

The treatment landscape for lung cancer has been transformed over the past decade by two paradigm-shifting developments: targeted therapy and immunotherapy. Molecular profiling of NSCLC has revealed oncogenic driver mutations — including EGFR, ALK, ROS1, KRAS G12C, MET, RET, BRAF V600E, and HER2 — in a significant proportion of tumors, for which specific targeted oral medications (EGFR inhibitors, ALK inhibitors, etc.) provide dramatic disease control and survival benefit compared to traditional chemotherapy. Immunotherapy with checkpoint inhibitors (PD-1/PD-L1 inhibitors: pembrolizumab, atezolizumab, nivolumab) has produced durable responses in a subset of patients whose tumors express high PD-L1 levels or are tumour mutational burden-high.

For early-stage lung cancer, surgical resection offers the best chance of cure. For locally advanced disease, concurrent chemoradiation followed by immunotherapy consolidation (durvalumab — the PACIFIC regimen) has significantly extended survival. For metastatic NSCLC, treatment is personalised based on molecular profile — targeted therapy for driver-mutation-positive tumors, immunotherapy-based regimens for high PD-L1 expressors, and chemotherapy-immunotherapy combinations for the remainder.

Comprehensive molecular testing of the biopsy specimen — at minimum EGFR, ALK, ROS1, KRAS, PD-L1 — is now standard of care for all newly diagnosed NSCLC patients and must be completed before systemic treatment is initiated.

Non-Small Cell vs. Small Cell Lung Cancer: Understanding the Difference

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer type. Its three main subtypes — adenocarcinoma (most common, typically in non-smokers and peripherally located), squamous cell carcinoma (associated with smoking, centrally located), and large cell carcinoma — are managed similarly from a staging and treatment perspective, though they differ in molecular profile patterns.

Small Cell Lung Cancer (SCLC) is an aggressive, rapidly dividing tumour with early widespread metastasis. It is strongly associated with heavy smoking. SCLC is staged as limited (confined to the ipsilateral hemithorax) or extensive (beyond); the vast majority of patients present with extensive stage. SCLC is initially highly sensitive to platinum-based chemotherapy and radiation but frequently recurs. Immunotherapy (atezolizumab or durvalumab added to chemotherapy) has recently extended survival in extensive SCLC.

Molecular profiling for NSCLC is critical: EGFR mutations are found in 15–50% of adenocarcinomas (higher in Asian non-smokers); ALK rearrangements in 3–7%; KRAS G12C mutations in approximately 13%. Next-generation sequencing (NGS) of the tumour tissue — and increasingly, liquid biopsy (circulating tumour DNA from blood) — provides comprehensive genomic profiling in a single test.

PD-L1 expression level, measured by immunohistochemistry on the tumour biopsy, predicts response to immunotherapy. High PD-L1 expressors (≥50%) may receive pembrolizumab monotherapy as first-line treatment for metastatic NSCLC without driver mutations, providing superior survival and quality of life compared to chemotherapy.

Who Is a Candidate for Lung Cancer Treatment?

All confirmed lung cancer patients require treatment evaluation. The specific approach is determined by histology, stage, molecular profile, performance status, and lung function.

Surgical candidates (NSCLC): Patients with clinical stage I–II NSCLC and adequate cardiopulmonary reserve are candidates for curative surgical resection. Pulmonary function tests (spirometry, DLCO) assess whether the patient's lung function can tolerate the proposed extent of resection. Lobectomy (removal of one lobe) is the standard; sublobar resection (wedge or segmentectomy) is used for patients with limited reserve or small peripheral tumors. Mediastinal staging (endobronchial ultrasound, EBUS, or PET-CT) must exclude nodal involvement before surgery.

Chemoradiation candidates (stage III NSCLC): Patients with unresectable stage III disease — due to mediastinal nodal involvement, T4 primary tumour, or patient comorbidities — are candidates for concurrent platinum doublet chemotherapy with thoracic radiation (60–66 Gy), followed by consolidation durvalumab immunotherapy for 12 months (the PACIFIC regimen, which doubled progression-free survival versus chemoradiation alone).

Systemic therapy candidates (stage IV NSCLC): All metastatic NSCLC patients without driver mutations and with PD-L1 ≥50% may receive pembrolizumab monotherapy. Driver-mutation-positive patients (EGFR, ALK, ROS1, KRAS G12C, MET, RET, BRAF, HER2) receive the corresponding approved targeted oral therapy as first-line treatment. The remainder receive platinum doublet chemotherapy combined with pembrolizumab.

Performance status (ECOG 0–2) is a key eligibility criterion for aggressive systemic therapy. Patients with ECOG 3–4 may not tolerate standard chemotherapy regimens.

Lung Cancer Surgery and Multimodal Treatment

Surgical resection — when feasible — offers the only potential cure for NSCLC. Video-Assisted Thoracoscopic Surgery (VATS) lobectomy is now the preferred approach at high-volume thoracic surgery centers: the same lobe removal is performed through 3–4 small port incisions using thoracoscopic cameras and instruments, avoiding the large chest wall incision and rib-spreading of traditional open thoracotomy. VATS lobectomy has equivalent oncological outcomes to open surgery with significantly less pain, shorter hospital stay (3–5 vs. 6–10 days), faster recovery, and lower complication rates.

Stereotactic Body Radiation Therapy (SBRT) — also called SABR — is an alternative to surgery for medically inoperable patients with early-stage peripheral NSCLC. Highly focused, ablative doses of radiation (typically 3–5 fractions) are delivered with millimetre precision to the tumour, achieving local control rates comparable to surgical resection in early-stage disease.

Systemic therapy for advanced NSCLC is increasingly oral: EGFR-mutant tumors receive osimertinib (3rd generation EGFR inhibitor, currently the most potent, approved for first-line); ALK-rearranged tumors receive alectinib or brigatinib; KRAS G12C-mutant tumors may now receive sotorasib or adagrasib. These targeted oral agents have transformed stage IV EGFR- and ALK-positive NSCLC from a rapidly fatal disease into a manageable chronic condition with median survival of 3–5+ years.

Procedure Steps

1. Tissue biopsy: CT-guided biopsy, bronchoscopy, or EBUS for tissue acquisition; histopathology, IHC, and comprehensive molecular profiling (EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, PD-L1).
2. Staging: PET-CT for metabolic staging; MRI brain (especially for adenocarcinoma); mediastinal staging by EBUS if surgical resection considered.
3. For surgical cases: pre-operative pulmonary function tests (spirometry, DLCO); cardiac assessment; anaesthesia review.
4. Thoracic surgery: VATS or robotic lobectomy/segmentectomy; mediastinal lymph node dissection for pathological staging.
5. Post-surgical pathological staging determines adjuvant treatment requirements (osimertinib for EGFR-mutant stage IB–III; chemotherapy for node-positive stage II–III).
6. For stage III: concurrent platinum doublet chemotherapy + thoracic radiation; consolidation durvalumab for 12 months.
7. For stage IV: first-line systemic therapy based on molecular profile — targeted therapy or immunotherapy-based regimen.
8. Radiological response assessment (CT chest/abdomen) every 8–12 weeks on systemic therapy; next-line therapy planned on progression.

Types of Lung Cancer Treatment

VATS / Robotic Surgical Resection

Video-assisted thoracoscopic surgery (VATS) or robot-assisted thoracoscopic surgery (RATS) lobectomy or segmentectomy for early-stage NSCLC. Performed through small port incisions without rib spreading. Current standard of care for surgical resection at experienced thoracic surgery programs. Shorter hospital stay, less pain, faster recovery than open thoracotomy.

Cost: $8,000 – $18,000

Targeted Oral Therapy (EGFR / ALK / Other Drivers)

Daily oral medications specifically targeting the oncogenic driver mutation present in the tumour. First-line osimertinib for EGFR-mutant NSCLC achieves median progression-free survival of 18 months; alectinib for ALK-rearranged NSCLC achieves 34-month median PFS. Oral administration means no infusion visits; main side effects are manageable rash and diarrhoea. Treatment continues until disease progression.

Cost: $800 – $4,000 per month

Immunotherapy (PD-1/PD-L1 Checkpoint Inhibitors)

Pembrolizumab, nivolumab, or atezolizumab — administered by intravenous infusion every 3–6 weeks. First-line pembrolizumab monotherapy for PD-L1 ≥50% NSCLC without driver mutations. Chemotherapy-immunotherapy combinations (carboplatin + pemetrexed + pembrolizumab) are standard for non-squamous NSCLC without driver mutations regardless of PD-L1 level. Immune-related adverse events (colitis, pneumonitis, thyroiditis) require proactive monitoring.

Cost: $1,500 – $6,000 per infusion

Stereotactic Body Radiotherapy (SBRT/SABR)

Ablative radiation therapy delivered in 3–5 high-dose fractions with millimetre precision to small peripheral lung tumors. Achieves local control rates comparable to surgery for early-stage disease in medically inoperable patients. No anaesthesia required; each session takes 30–60 minutes. Often used for patients who decline surgery or have inadequate cardiopulmonary reserve for resection.

Cost: $5,000 – $12,000 (full course)

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

United States — $100,000 – $400,000 (full treatment) — Baseline

United Kingdom — $30,000 – $80,000 — ~75% vs. USA

Germany — $25,000 – $70,000 — ~78% vs. USA

India — $8,000 – $25,000 — Up to 90% vs. USA

UAE — $25,000 – $70,000 — ~70% vs. USA

Lung cancer treatment costs accumulate over the treatment course, particularly for patients receiving prolonged targeted therapy or immunotherapy. The cost of osimertinib in the USA exceeds $17,000 per month; generic osimertinib is available at internationally accredited programs for $400–$800 per month — a 95% cost reduction with equivalent clinical efficacy. Pembrolizumab biosimilars are similarly available at dramatically lower cost at internationally approved oncology programs.

Surgical costs are a one-time episode; systemic therapy for stage IV disease is ongoing. Gaf Healthcare helps patients plan realistically for both the acute treatment episode and the ongoing systemic therapy phase, with transparency about cost at each decision point.

Recovery & Follow-up

Recovery from VATS lobectomy is significantly faster than open thoracotomy. Hospital stay is typically 3–5 days; a chest drain is removed once daily drainage is minimal. Pain is manageable with oral analgesics; most patients are walking by day 2. Return to light activity occurs within 3–4 weeks; full activity by 6–8 weeks. Pulmonary rehabilitation — supervised breathing exercises — accelerates recovery of lung function.

Recovery on targeted therapy or immunotherapy is generally outpatient. Patients on daily oral targeted therapy experience manageable rash, diarrhoea, and fatigue. Immunotherapy infusions are given every 3–6 weeks; immune-related adverse events require prompt recognition and management. Quality of life on modern targeted oral therapy is significantly better than on traditional chemotherapy.

Recovery Tips

• Practice deep breathing exercises (incentive spirometry) aggressively from day one post-surgery — prevents pneumonia and speeds lung re-expansion.
• Walk progressively every day from surgery onwards; ambulation is the most important early post-operative intervention.
• Report any new or worsening breathlessness, fever, or chest pain immediately after surgery — these may indicate post-operative pneumonia or bronchopleural fistula.
• Take targeted therapy tablets at the same time every day with or without food as specified; never self-adjust the dose.
• Report any skin rash, severe diarrhoea, or joint inflammation during immunotherapy immediately — immune-related adverse events require specialist assessment.
• Attend every scheduled CT restaging — early detection of progression or resistance enables timely treatment change.
• Stop smoking immediately and permanently — continued smoking during treatment significantly worsens outcomes and increases treatment toxicity.
• Maintain adequate nutrition and hydration; lung cancer and its treatment cause significant fatigue and appetite loss that worsen outcomes if not actively managed.

Risks & Complications

Surgical risks for VATS lobectomy include prolonged air leak (most common complication, managed with continued chest drainage), pneumonia, atrial fibrillation, and bronchopleural fistula (rare but serious). Operative mortality at high-volume thoracic centers is below 1–2% for elective lobectomy in fit patients. Residual breathlessness after lobectomy is common but typically well-tolerated if pre-operative lung function was adequate.

Targeted therapy toxicities are drug-specific: EGFR inhibitors cause skin rash, diarrhoea, and paronychia; ALK inhibitors cause visual disturbances and nausea. Serious toxicities are uncommon. Immunotherapy carries risk of immune-related adverse events affecting any organ system — colitis, pneumonitis, hepatitis, thyroiditis, and nephritis. These are managed with corticosteroids and, for severe cases, drug discontinuation.

Why GAF Healthcare

Lung cancer requires comprehensive molecular diagnostic capability, multidisciplinary expertise, and access to current-generation targeted and immunotherapy agents. Gaf Healthcare works with oncology centres that offer next-generation sequencing, multidisciplinary tumor boards, VATS surgical capability, and access to approved targeted agents and immunotherapy. We facilitate rapid molecular testing result review and rapid treatment plan confirmation for patients whose disease cannot wait for weeks of administrative delay.

Frequently Asked Questions

What is molecular profiling and why is it essential?

Molecular profiling identifies the specific genetic mutations or alterations driving your lung cancer's growth. For the 50–60% of NSCLC patients with a targetable driver mutation (EGFR, ALK, ROS1, KRAS G12C, etc.), there is now a specific oral medication that dramatically outperforms chemotherapy. Starting the wrong treatment (chemotherapy when a targeted agent is indicated) costs precious months of response. Comprehensive molecular testing — at minimum a broad NGS panel — must be completed before any systemic therapy begins for newly diagnosed NSCLC.

Is VATS surgery as safe and effective as open lung surgery?

Yes — multiple randomised controlled trials and large registry studies have confirmed equivalent oncological outcomes (survival, locoregional recurrence rates) between VATS and open lobectomy for stage I–II NSCLC. VATS provides significantly less post-operative pain, shorter chest drain duration, shorter hospital stay (3–5 vs. 6–10 days), lower post-operative complication rates, and faster return to normal activities. VATS is now the preferred approach at experienced thoracic surgery centers globally.

Can lung cancer be treated without surgery?

For early-stage peripheral NSCLC in patients who are medically inoperable, stereotactic body radiotherapy (SBRT/SABR) achieves local control rates comparable to surgery in randomised trials. For stage III disease, concurrent chemoradiation is the standard of care. For stage IV, surgery plays no primary role except for isolated metastases in selected patients; systemic therapy is the cornerstone. The decision on whether surgery, radiation, or systemic therapy is appropriate requires comprehensive multidisciplinary evaluation.

How effective is immunotherapy for lung cancer?

Immunotherapy has transformed lung cancer outcomes for eligible patients. Pembrolizumab monotherapy for high PD-L1 expressors (≥50%) achieves 5-year overall survival of approximately 26% in metastatic NSCLC — compared to approximately 5% historically with chemotherapy alone. Chemotherapy-immunotherapy combinations benefit patients with lower or absent PD-L1 expression. Immunotherapy is not effective for EGFR-mutant or ALK-rearranged NSCLC, where targeted therapy is far superior.

What is the role of liquid biopsy in lung cancer management?

Liquid biopsy — analysis of circulating tumour DNA (ctDNA) from a blood sample — offers several advantages over tissue biopsy for lung cancer. It can detect the same driver mutations as tissue biopsy without a surgical procedure, making it particularly useful when tumour tissue is limited or inaccessible. It is also used to detect resistance mutations when a targeted therapy stops working — EGFR T790M (the most common EGFR resistance mutation) can be detected in blood before the patient is even symptomatic. Liquid biopsy is now part of routine lung cancer management at comprehensive cancer centres.

How long does targeted therapy work before resistance develops?

First-line osimertinib for EGFR-mutant NSCLC achieves a median progression-free survival of approximately 18 months. Alectinib for ALK-rearranged NSCLC achieves approximately 34 months. However, every patient eventually develops resistance. When progression occurs, liquid biopsy and/or repeat tissue biopsy identifies the resistance mechanism, and the next-line treatment is selected accordingly. The sequential use of multiple targeted agents can extend total treatment benefit to 4–6+ years in some patients.